On March 21, 2025, the pharmaceutical industry achieved frequent successes in innovative research and development and global market expansion, with multiple companies demonstrating strong development momentum.
China Biopharmaceuticals has released its 2024 annual report, achieving remarkable results. The annual operating revenue reached 28.87 billion yuan, a year-on-year increase of 10.2%; The profit attributable to the shareholders of the parent company was 3.5 billion yuan, a year-on-year increase of 50.1%. What is even more remarkable is that it has achieved fruitful results in the field of innovative drugs. In 2024, a total of 6 innovative products were approved for market, including 4 national Class 1 innovative drugs, ranking first in the industry and demonstrating strong research and development capabilities.
In contrast, due to a decline in performance in 2024, Huateda achieved a revenue of 2.134 billion yuan, a year-on-year decrease of 14.08%; The net profit attributable to the parent company was 516 million yuan, a decrease of 11.90%. Its business mainly relies on the children's health industry of its subsidiary, Dain Pharmaceutical, and this single business structure carries significant risks during market fluctuations.
In the field of innovative drug research and development, Junshi Biotechnology has made significant breakthroughs. Its first ADC dual antibody drug JS212 has been approved for clinical use, mainly for the treatment of advanced malignant solid tumors, with broad market prospects. On the same day, GenSci120 injection from Jinsai Pharmaceutical also obtained implied approval from the US FDA for use in patients with rheumatoid arthritis. Previously, the drug has been approved for multiple clinical trials in China, which is expected to further enrich the company's product line.
Time Angel has performed well in the invisible orthodontic market, achieving revenue of $269 million in 2024, a year-on-year increase of 28.2%; Net profit of 10 million US dollars, an increase of 46.6% year-on-year. Especially in overseas markets, the number of invisible orthodontic cases has increased by 326.4%, demonstrating strong international expansion capabilities.
